Retrotope announces the opening of second clinical trial site, the Collaborative Neuroscience Network, LLC. ("CNS") in Long Beach, California, for the ongoing 28-day, first-in-human randomized, double-blind, controlled, ascending dose study of orally dosed RT001 to evaluate the safety, tolerability, pharmacokinetics (PK), disease state, and exploratory endpoints in patients with Friedreich's ataxia (FA). This site is a specialized facility that is experienced with running Phase 1 studies for neurological diseases. We need about 10 additional subjects to enroll in this study and hope that a site in California aids in subject participation.

Read the entire article HERE